Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc
Go

Financials : Banks | Large Cap Value
Company profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Postmarket

Last Trade
Delayed
$24.92
0.02 (0.08%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$24.90
Day's Change
0.03 (0.12%)
Bid
--
Ask
--
B/A Size
--
Day's High
25.26
Day's Low
24.71
Volume
(Below Average)
Volume:
51,007,411

10-day average volume:
60,730,446
51,007,411

Rising Incidence Of Viral Diseases And Increase In Elderly Population Are Causing Growth In The Anti-Viral Drug Therapy Market Size

6:00 am ET October 1, 2020 (Globe Newswire) Print

(Anti-Viral Drug Therapy Companies Included: AbbVie Inc., Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Dr. Reddy's Laboratories Ltd, AstraZeneca plc., Aurobindo Pharma, Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., Novavax, Inc., BioCryst Pharmaceuticals, Inc.)

The global anti-viral drug market size reached a value of nearly $46.45 billion in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46.45 billion in 2019 to $ 61.57 billion in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74.38 billion in 2023. The market is expected to reach $87.23 billion in 2025, and $130.12 billion in 2030.

The Business Research Company's report titled Anti-Viral Drug Therapy Global Market Report 2020-30: COVID-19 Implications and Growth covers major anti-viral drug therapy companies, anti-viral drug therapy market share by company, anti-viral drug therapy manufacturers, anti-viral drug therapy market size, and anti-viral drug therapy market forecasts. The report also covers the global anti-viral drug therapy market and its segments. The anti-viral drug therapy market is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, others and by application into HIV, hepatitis, herpes, influenza, others.

Request For A Sample Of The Global Anti-Viral Drug Therapy Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2831&type=smp

North America was the largest region in the global anti-viral drug therapy market, accounting for 50.6% of the total in 2019. It was followed by Asia Pacific and Western Europe, and then the other regions. The anti-viral drug therapy market share in North America is supported by the presence of a large patient population, high prevalence of diseases such as influenza and HIV/AIDS, high medical expenditure and high insurance coverage in countries such as the USA and Canada.

The market is also supported by R&D spend on drug therapies in the region. The USA has the highest number of COVID-19 infections in the world, and this will further drive the demand for antiviral drugs, thereby supporting the market for antiviral drug therapy in the region.

The market has taken on several methods to handle the demand during this pandemic. Some antiviral drug therapy market trends are how companies in the anti-viral drug therapy market are strategically partnering and collaborating with other companies to broaden their product portfolios and expand their anti-viral drug therapy business, while pharmaceutical companies and federal governments are increasingly working together in partnerships and collaborations as well, to provide funding and implement incentive programs for the research and development of anti-viral drugs. These partnerships provide financial and technical assistance across different clinical development phases to pharmaceutical companies.

Companies are also increasingly focusing on the development and launch of combination drug therapies for treating HIV and other viral infections. Combination therapy involves the formulation of different drugs for treating different diseases. Combination therapy for treating viral infections has been proved effective in suppressing the replication of viruses and reducing antiviral resistance. 3D bioprinting technology is being adopted in the development and manufacturing processes of anti-viral drugs to reduce manufacturing costs and increase production efficiencies and to expedite the process of drug discovery.

Anti-viral drug therapy companies and research institutes are increasing the number of pipeline studies to develop anti-viral drugs for treating rare infectious diseases. Currently, there are 728 potential drugs in the pipeline against COVID-19, major ones being Remdesivir and Dexamethansone.

Anti-Viral Drug Therapy Global Market Report 2020-30: COVID-19 Implications and Growth is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole anti-viral drug therapy market, anti-viral drug therapy market segments and geographies, anti-viral drug therapy market trends, anti-viral drug therapy market drivers, anti-viral drug therapy market restraints, anti-viral drug therapy market leading competitors' revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors' approaches.

Here Is A List Of Similar Reports By The Business Research Company:

Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change

Remdesivir Market Global Report 2020-30: COVID 19 Growth and Change

Anti-Infective Drugs Market - By Type Of Product (Antibiotics, Antivirals, Antifungals And Others (Including Anthelminthic And Antiprotozoal Drugs)), And By Region, Opportunities And Strategies - Global Forecast To 2022

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Follow us on Twitter: https://twitter.com/tbrc_info

https://ml.globenewswire.com/media/3bf07720-8041-4b6e-84f3-8c3f28854315/small/the-business-research-company-horizontal-logo-2-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.